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Immunotherapy-based strategies for gastrointestinal carcinomas (GIC) have been exploited
so far, but these approaches have to face strong mechanisms of immune escape induced by
tumours. We previously demonstrated that sub-therapeutic doses of an adenovirus ex-
pressing IL-12 genes (AdIL-12) mediated a potent antitumour effect against subcutaneous
(s.c.) colorectal carcinomas (CRC) in mice pre-treated with low doses of cyclophosphamide
(Cy). In our study we used this combination to assess its impact on the immunosuppressive
microenvironment. In s.c. CRC model we demonstrated that non-responder mice failed to
decrease Tregs in tumour, spleen and peripheral blood. Reconstitution of Tregs into
tumour-bearing mice treated with combined therapy abolished the antitumoural effect.
In addition, Cy þ AdIL-12 modified Tregs functionality by inhibiting the in vitro secretion
of IL-10 and TGF-b and their ability to inhibit dendritic cells activation. Combined treat-
ment decreased the number of myeloid-derived suppressor cells (MDSCs) in comparison
to non-treated mice and, interestingly, administration of Tregs restored splenic MDSCs
population. Furthermore, combined therapy potently generated specific cytotoxic IFN-g-
secreting CD4þ T cells able to eradicate established CRC tumours after adoptive transfer.
Finally, we evaluated the combination on disseminated CRC and pancreatic carcinoma
(PC). Cy þ AdIL-12 were able to eradicate liver metastatic CRC (47%) and PC tumour nodules
(40%) and to prolong animal survival. The results of this study support the hypothesis that
Cy þ AdIL-12 might be a valid immunotherapeutic strategy for advanced GIC.
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M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 1 ) 1e1 421. IntroductionPotent mechanisms of immunosuppression are active during
immunostimulatory monoclonal antibodies, dendritic cells,
and other immunotherapy approaches (Gomez et al., 2001;this cytokine with other procedures, such as chemotherapy,tumour growth limiting the effectiveness of immunotherapy
strategies (Zou, 2005). Mechanisms used by malignant
tumours to elude immune recognition include tumour-
induced impairment of antigen presentation, activation of
negative co-stimulatory signals and secretion of immunosup-
pressive factors (Almand et al., 2001; Bell et al., 1999;
Ghiringhelli et al., 2005; Nestle et al., 1997). In addition, cancer
cells may induce the expansion and/or recruitment of regula-
tory cell populations that may promote and sustain this im-
munosuppressive network; these populations include
regulatory T cells (Tregs), myeloid-derived suppressor cells
(MDSCs) and distinct subsets of immature andmature regula-
tory dendritic cells (DCs) (Croci et al., 2007).
Colorectal carcinoma (CRC) is the second most common
cause of cancer mortality in western countries and the 9.7%
of the most commonly diagnosed cancers worldwide (Ferlay
et al., 2010). Twenty five percent of the patients have meta-
static disease at diagnosis, and their predicted 5-year survival
among non-surgical patients is less than 10% (Lorenz et al.,
2000). Pancreatic cancer is the fourth leading cause of
cancer-related death and surgery is the only curative option;
however, more than 80% of the patients showed local or dis-
seminated recurrence (Lorenz et al., 2000). Therefore, there
is an urgent need for new therapeutic strategies for advanced
GIC. During the last two decades multiple immunotherapy-
based strategies for GIC have been developed with promising
results not only at preclinical stage but also in the clinic
(Elkord et al., 2008; Shapira et al., 2010). The loss/down regula-
tion of MHC class I antigens, the lack of co-stimulatory mole-
cules, defective death receptor signalling, apoptosis of
activated T cells, immunosuppressive cytokines, and activa-
tion of suppressor T cells have been described as responsible
for the failure of anticancer treatment in mice and humans
(Mazzolini et al., 2007).
Interleukin 12 (IL-12), a cytokine with multiple biological
effects, is one of the most potent antitumour cytokines
(Mazzolini et al., 2003; Trinchieri, 2003). However, high doses
of IL-12 are needed to achieve significant antitumour effects
that results in severe toxicity (Leonard et al., 1997). In recent
years, gene therapy has emerged as a therapeutic tool to allow
desired levels of IL-12 or other cytokines into tumoural/peritu-
moural milieu avoiding undesired side effects (Colombo and
Forni, 1994). The efficacy of IL-12 gene transfer for advanced
GIC in animal models has been shown consistently by differ-
ent research groups including ours (Barajas et al., 2001;
Caruso et al., 1996; Mazzolini et al., 1999; Putzer et al., 2001).
Intratumoural administration of an adenovirus expressing
IL-12 genes (AdIL-12) in patients with advanced GIC in a phase
I trial was a feasible and well-tolerated procedure that exerted
only mild antitumoural activity (Sangro et al., 2004). Immuno-
suppressive activity induced by tumoural and peritumoural
cells seem to be critical and might be responsible for the
lack of clinical success in immune- and non immune-based
therapies (Rabinovich et al., 2007; Zwirner et al., 2010). Seeking
for immunotherapeutic synergies to fight against cancer, it
was possible to increase the efficacy of IL-12, by combiningPlease cite this article in press as: Malvicini, M. et al., Reversal of g
induction of antitumoural immunity by a combination of cyclop
(2011), doi:10.1016/j.molonc.2011.03.007Melero et al., 2001). Cyclophosphamide (Cy) is a widely known
chemotherapeutic agent that displays either immunosup-
pressive or immunopotentiating effects, depending on the
dosage and the duration of administration of this drug
(Brodsky et al., 1998; Colvin, 1999). Several mechanisms have
been proposed to explain Cy immunomodulatory activity in-
cluding depletion of tumour-induced regulatory T cells, pro-
duction of soluble growth factors, Th2/Th1 shift in cytokine
production, and others (Ghiringhelli et al., 2004; Matar et al.,
2002; Proietti et al., 1998). However, the precise mechanism
is not yet clarified.
Recently, we have shown a novel synergistic combination
of Cy and AdIL-12 for the eradication of CRC in mice. Cur-
rently, we explored the mechanisms of action between Cy
and AdIL-12 combination and observed that the potent anti-
cancer effect obtained in advanced GIC is based on their capa-
bility to block Tregs secretion of IL-10 and TGF-b cytokines, as
well as on the loss of their inhibitory activity exerted on DCs.
In addition, we observe a decrease in the number of MDSCs af-
ter Tregs inhibition. Finally, combined treatment showed syn-
ergistic activity not only at the induction of the immune
response but also at the effector phase by generating potent
IFN-g-secreting CD4þ T cells that were able to eradicate estab-
lished CRC tumour nodules.2. Materials and methods
2.1. Animals and cell lines
Six- to eight-week-old male BALB/c mice and C57BL/6 mice
were purchased fromCNEA (National Atomic Energy Commis-
sion, Ezeiza, Argentina). Animals were maintained at our An-
imal Resource Facilities (School of Biomedical Sciences,
Austral University) in accordance with the experimental ethi-
cal committee and the NIH guidelines on the ethical use of an-
imals. The CT26 (colorectal carcinoma), BNL (hepatocellular
carcinoma) and Panc02 (pancreatic carcinoma) tumour cell
lines were used (kindly provided by Prof. Prieto, University of
Navarra, Spain). Cells were maintained in DMEM or RPMI
1640 supplemented with 10% heat-inactivated FCS, 2 mmol/
L L-glutamine, 100 U/mL streptomycin, and 100 mg/mL peni-
cillin and incubated at 37 C in a 5% CO2 humidified
atmosphere.2.2. Drugs
Cyclophosphamide (Filaxis, Argentina) was dissolved in ster-
ile water at a concentration of 20 mg/mL and injected i.p. at
the indicated dose.2.3. Adenoviral vectors
Construction of a recombinant adenovirus encoding for IL-12
(AdIL-12) was previously described (Mazzolini et al., 1999).astrointestinal carcinoma-induced immunosuppression and
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CT26 cells were injected at a dose of 5  105 cells s.c. into the
right flank of BALB/c mice (day 0). Tumours were allowed to
reach approximately 85 mm3 in size before treatment was
started. Animals were distributed in different groups and
then treated with saline i.p.; Cy (50 mg/kg i.p., day 8); AdIL-
12 (109 TCID50 intratumourally (i.t.), day 9); Cy (50 mg/kg
i.p.) þ AdIL-12 (109 TCID50 i.t.). Adenovirus were diluted in sa-
line (final volume 50 mL) and i.t. injected in a single site; no
leakage of material was observed after inoculations.
2.4.2. Adoptive transfer of CD4þCD25þ T cells (Tregs)
CT26 tumour-bearing mice (approximately 85 mm3 in size)
were i.p. treated with saline or Cy (50 mg/kg i.p, day 8) þ AdIL-
12 (109 TCID50 i.t, day 9). Forty-eight and 96 h later, mice were
injected i.v with 1  106 CD4þCD25þ T lymphocytes isolated
by magnetic cell sorting from spleen of non-treated tumour-
bearingmice excised at day 14 of tumour growth evolution.
2.4.3. Adoptive transfer of CD4þCD25 T cells2.4.3.1. Preventive model. BALB/c mice were simultaneously
inoculated with 5  105 CT26 cells s.c. into the right flank, and
with 2.5  106 CD4þCD25 cells i.v., isolated by magnetic cell
sorting and in vitro re-stimulated, from spleen of saline, Cy,
AdIL-12 or Cy þ AdIL-12-treated mice (see Section 2.13 below).
2.4.3.2. Therapeutic model. CT26 tumour-bearing mice (appr-
oximately 65 mm3 in size) were adoptively transferred with
2.5  106 CD4þCD25 cells i.v., isolated by magnetic cell sort-
ing, from saline, Cy, AdIL-12 or Cy þ AdIL-12-treated mice.
2.4.4. Pancreatic tumour model
C57BL/6 mice were inoculated in the right flank with 5  105
Panc02 cells s.c. When tumours reached 85 mm3 in size, ani-
mals were treated with saline, Cy (50 mg/kg i.p., day 8),
AdIL-12 (109 TCID50 i.t., day 9) or Cy þ AdIL-12. Tumour
growth was assessed twice a week by calliper.
2.4.5. Liver metastatic CRC model
BALB/c mice received an intra-hepatic inoculation of 5  105
CT26 cells (day 0). Then, mice were distributed in experimen-
tal groups and treated with saline; Cy (50 mg/kg i.p., day 8);
AdIL-12 (109 TCID50 i.t., day 9) or Cy þ AdIL-12. At day 20, an-
imals were sacrificed and the volume of metastatic nodules
were measured with calliper.2.5. Sample preparation for Tregs and MDSCs cytometry
analysis
BALB/c mice were injected with 5  105 CT26 cells s.c. into the
right flank (day 0) and tumours were allowed to reach 85 mm3
before the beginning of the treatment. For Tregs analysis, ani-
mals were distributed and treated with saline or Cy þ AdIL-12.
Atday15and22 (7and14dayspost-treatment),peripheralblood
was collected by cardiac puncture and anticoagulated with
EDTA. Single splenic and tumoural cell suspensions werePlease cite this article in press as: Malvicini, M. et al., Reversal of g
induction of antitumoural immunity by a combination of cyclop
(2011), doi:10.1016/j.molonc.2011.03.007obtainedbymechanicaldisruptionandthentreatedwithRBCly-
sis buffer (0.15mol/L NH4Cl, 1mmol/L KHCO3, 0.1mmol/L Na2-
EDTA) and washed with PBS 1% bovine serum albumin, before
flow cytometry analysis. For MDSCs analysis, tumour-bearing
animals were distributed into different groups and treated
with saline, Cy, AdIL-12 or Cy þ AdIL-12. The mice were sacri-
ficedonday15, spleenswereexcisedandsinglecell suspensions
were prepared for flow cytometry analysis as described below.
MDSCs were phenotypically characterized as CD11bþ Gr1þ.
2.6. Generation of bone marrow-derived DCs
DCswere generated from BALB/cmice as described elsewhere
(Alaniz et al., 2009). Flow cytometric analysis for CD11c and
the capacity to produce IL-12 after LPS activation was per-
formed to certify the presence and functional status of gener-
ated DCs at the end of procedure.
2.7. Cell purification by magnetic cell sorting
Spleen cell suspensions were obtained by mechanical disrup-
tion of spleen from CT26-bearing mice treated with saline, Cy,
AdIL-12 or Cy þ AdIL-12. CD4þCD25þ and CD4þCD25 cells
were purified bymagnetic cell sorting using amouse T regula-
tory cell isolation kit and LD plusMS columns according to the
manufacturers’ instructions (Miltenyi Biotec, Auburn, CA,
USA). CD4þCD25þ cells (Tregs) obtained were >95% in purity
by flow cytometric analysis of intracellular Foxp3.
2.8. Expansion of CD4þCD25þ T cells and co-culture
with DCs
Purified CD4þCD25þ T cells were cultured for 48h with rmIL-2
(10 UI/ml) (Peprotech, Rocky Hill, NJ, USA). Supernatants were
collected and used for allogeneic splenocytes proliferation as-
say and cytokines quantification. Tregs and DCs (ratio ¼ 1:1)
were co-cultured for 24 h and then LPS (Sigma Chemicals, St
Louis, MO, USA) was added (1 mg/ml) for additional 24 h.
2.9. Cell labelling
Tregs were labelled with the fluorescent dye Fast DiO (Molec-
ular Probes, Eugene, USA) according to the manufacturer in-
structions. Briefly, cells were incubated with 3 mM Fast DiO
cell solution for 5 min at 37 C in 5% CO2-humidified atmo-
sphere and for 15 min at 4 C and then washed with PBS. After
labelling Fast DiO-stained Tregs were diluted in saline and i.v.
injected into mice. Five days later, peripheral blood was col-
lected and mice were sacrificed. Spleen, liver, tumour and re-
gional lymph nodes were excised from each animal and single
cell suspensionswere obtained by digestionwith collagenase I
(Calbichem, Merck KGaA, Darmstadt, Germany). The cell
suspension was treated with RBC lysis buffer, washed with
PBS 1% bovine serum albumin, fixed in 1% paraformaldehyde
and then analysed by flow cytometry (FACSAria, BD).
2.10. Flow cytometry
Peripheral blood mononuclear cells, tumour cells or spleno-
cytes were stained with the following conjugated antibodies:astrointestinal carcinoma-induced immunosuppression and
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Biosciences), allophycocyanin-anti-CD11b (BD Biosciences),
PE-anti-Gr1 (BD Bioscience) and their respective isotypes.
DCs were stained with APC-anti-CD11c (kindly provided by
Dr. Gabriel Rabinovich, IByME, Argentina), PE-anti-MHCII (BD
biosciences), FITC- anti-CD40 (BD biosciences) and their re-
spective isotypes. Cells were fixed with 1% paraformaldehyde
and subjected to flow cytometry (FACSAria, BD). Data were
analysed using WinMDI software.
2.11. Cytokine quantificationby ELISA
Transforming growth factor-b (TGF-b), IL-10 and IL-12 concen-
trations in culture supernatants were measured by specific
ELISA kits (OptEIA, BD Biosciences Pharmingen for IL-10 and
IL-12 and R&D Systems for TGF-b). Assays were carried out
according to the instructions provided by the manufacturers.
2.12. Allogeneic splenocytes proliferation assay
Bone marrow-derived DCs (1  105) from BALB/c mice were
treated for 20 min with 50 mg/ml mitomycin C (Sigma Chemi-
cal,St. Louis, MO, USA), washed and used as stimulators. Sple-
nocytes (1  106) from na€ıve C57BL/6 mice were plated in
U-bottom 96-well plates at a ratio of 1:10 (DCs: splenocytes).
Assays were carried out in the presence of Tregs supernatants
derived from saline, Cy, AdIL-12 or Cy þ AdIL-12-treatedmice.
Cell proliferation was evaluated after 4 days in culture, as de-
scribed elsewhere (Malvicini et al., 2009).
2.13. In vitro re-stimulation of CD4þCD25 T cells
BALB/c mice were injected with CT26 cells and treated with
Cy, AdL-12 or Cy þ AdIL-12 as described above. Splenocytes
were isolated 14 days after treatment and CD4þCD25 T cells
were obtained by immunomagnetic selection. Then, purified
CD4þCD25 T cells were pooled, and 4  106cells/ml were
co-cultured with mitomycin C-treated CT26 cells (4  105/ml)
and mitomycin C-treated splenocytes (4  105/ml) in a 24-
well plate (1 ml/well) with 10 UI/ml rmIL-2. Seven days later,
viable cells were harvested and washed, adjusted to 4  106/
mL, and co-cultured again with mitomycin C-treated CT26
cells and splenocytes. On day 14, CD4þCD25 T cells were
used for in vivo adoptive T cells transfer experiments.
2.14. Statistical analysis
Mann Whitney, KruskaleWallis tests and KaplaneMeier, log
rank (InStat, GraphPad Software) were used to statistically ex-
amine the differences between groups. P < 0.05 was consid-
ered statistically significant.3. Results
3.1. Tregs depletion is required to generate an effective
antitumoural response after treatment with Cy þAdIL-12
We previously demonstrated that the sequential administration
of Cy followed by adenoviral gene transfer of IL-12 inducedPlease cite this article in press as: Malvicini, M. et al., Reversal of g
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(2011), doi:10.1016/j.molonc.2011.03.007a synergistic antitumoural effect on s.c. CRC model (CT26)
(Malvicini et al., 2009). Two well defined groups were found in
Cy þ AdIL-12-treated mice. The two categories were identified
as responders (R) and non-responders (NR) mice, depending on
whether they showed a >50% in tumour size reduction or not.
Post-treatment tumour sizes in NR mice at days 7 and 14 post-
treatment were significantly higher (566  143 and
614  92 mm3, respectively) than in R mice (58  19 and
126  58 mm3, respectively) ( p < 0.01) (Fig. 1A). To determine
whether immunosuppressiveTcell-mediatedmechanismscould
be involved in the observed differential antitumoural response
obtained after treatment with Cy þ AdIL-12, we first analysed
the prevalence of Tregs in peripheral blood and spleens using
triple-staining flow cytometry. While the levels of CD4þ T cells
were similar for either untreatedmice or treatedwith the combi-
nation(Supplementaryfigure#1), thepercentageofTregswassig-
nificantlyhigher inNRthaninRmice ( p<0.05), inbothperipheral
blood and spleens (Fig. 1B and C). In addition, we observed an in-
crease in the percentage of tumour-infiltrating CD4þ cells in R
mice compared to NR and saline groups ( p < 0.05; Fig. 1D, left
panel). The tumour-infiltrating CD4þCD25þFoxp3þ/CD4þ pro-
portion were evaluated in the same experiment. The percentage
of Tregs in R was significantly lower than in untreated mice
(P< 0.05, Fig. 1D, right panel). On day 14, the percentage of intra-
tumouralTregs inRwas lower than inNRandsaline-treatedmice
( p < 0.05), in agreement with the results obtained in peripheral
blood and spleen. These results showed an association between
increased circulating and tumour-infiltrating Tregs with tumour
resistance to combined Cyþ AdIL-12 therapy. These results indi-
cate thatdepletionofTregs iscritical toachieveatherapeuticben-
efit in CT26 CRC-bearingmice.
Toconfirmthe inhibitory effect ofTregson theantitumoural
efficacy of combined therapy, we adoptively transferred
CD4þCD25þFoxp3þ T cells into CT26 tumour-bearing mice
that were treated with the combination. Thus, 1  106
CD4þCD25þFoxp3þ T cells derived from untreated tumour-
bearingmice were administered i.v. on days 11 and 13 after tu-
mour inoculation (days 2 and 4 after the combined treatment
withCyþAdIL-12). Asa result, adoptive transfer ofTregs signif-
icantly abolished the antitumoural effect achieved with the
combined treatment (mean tumour volume  SE [mm3] at day
28, Cy þ AdIL-12: 144  81 vs. Cy þ AdIL-12þTregs: 3191  394,
p < 0.01; Fig. 2A). Moreover, animal survival was strongly re-
duced after adoptive transfer of Tregs, showing a similar value
in saline group (Fig. 2B). The trafficking behaviour of adminis-
tered Tregs was also analysed. Interestingly, FastDio-stained
Tregs injected i.v. revealed that Tregsweredistributed indiffer-
ent organs,with higher levels in peripheral blood, lymphnodes
and tumours (Fig. 2C).Altogether, these results strongly suggest
that, at least in this tumour model, CD4þCD25þFoxp3þ T cells
should be inhibited in order to achieve a potent antitumoural
immune response.
3.2. Combined therapy with Cy þ AdIL-12 reverts the
inhibitory effects of Tregs on DCs activation
Weinvestigated theeffectsofCyþAdIL-12on the immunosup-
pressive functions of Tregs derived fromCT26 tumour-bearing
mice. Thus, we decided to assess the effects of combined ther-
apy on the ability of Tregs tomodulate not only thenumber butastrointestinal carcinoma-induced immunosuppression and
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Fig. 1 e Assessment of Tregs in mice R (responder) and NR (non-responders) to combined treatment CyD AdIL-12 in s.c CT26 tumour model.
(A) Tumour volume in R and NR mice. BALB/c mice (n[ 35) were s.c. inoculated with 53 105 CT26 cells into the right flank (day 0) and tumours
were allowed to reach 85 mm3 before the treatment began. Animals were treated with Cy (50 mg/kg i.p., day 8)D AdIL-12 (109 TCID50 i.t., day
9) (n [ 12) or with saline (n [ 6). Tumour growth was assessed twice a week by calliper. Tumour volumes at days 7 and 14 after treatment are
expressed as mean (bars, SEM). The experiment was performed four times. Mann Whitney test, Cy D AdIL-12 NR vs. Cy D AdIL-12 R:
(##p< 0.01). Percentage of CD4þCD25þFoxp3þ/CD4þ cells in peripheral blood (B) or spleen (C) of R and NR mice. Mann Whitney test, Peripheral
blood, day 7 and day 14: CyD AdIL-12 R vs. saline (**p< 0.01) and vs. CyD AdIL-12 NR (#p< 0.05). Spleen, day 7: CyD AdIL-12 R vs. saline
and CyD AdIL-12 NR (#p< 0.05); CyD AdIL-12 NR vs. saline (*p< 0.05); day 14: CyD AdIL-12 R vs. saline and CyD AdIL-12 NR (*and
#p< 0.05). (D) Percentage of tumour-infiltrating CD4þ Tcells (left) and CD4þCD25þFoxp3þ/CD4þ cells (right). ManneWhitney test, CD4þ
Tcells, day 7: CyD AdIL-12 R vs. saline, (*p< 0.05); day 14: CyD AdIL-12 R vs. saline and CyD AdIL-12 NR (#p< 0.05); CyD AdIL-12 NR
vs. saline (*p< 0.05). CD4þCD25þFoxp3þ/CD4þ cells, day 7: CyD AdIL-12 R vs. saline, (*p< 0.05); day 14: CyD AdIL-12 R vs. saline and
Cy D AdIL-12 NR (#p< 0.05). The results shown represent four independent experiments.
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end, na€ıve DCs were co-cultured with Tregs isolated from dif-
ferent experimental groups. When DCs were cultured with
saline-derived Tregs there was a significant reduction in the
production of IL-12 as well as in the expression of MHC-II and
the CD40 co-stimulatory molecules induced by LPS ( p < 0.05,
Fig. 3A andB). In contrary,whenDCswere cultured in the pres-
ence of Cy þAdIL-12-treated mice-derived Tregs, they showed
a similar pattern of activation, IL-12 production and MHC-II-
CD40 expression phenotype than the observed in control DCs
after LPS stimulation.
3.3. Combined therapy with Cy þ AdIL-12 reverts Tregs-
immunosuppressive phenotype by reducing IL-10 and TGF-b
production
We investigate in vitro the secretion of IL-10 and TGF-b by
Tregs derived from spleens of CT26 tumour-bearing mice,Please cite this article in press as: Malvicini, M. et al., Reversal of g
induction of antitumoural immunity by a combination of cyclop
(2011), doi:10.1016/j.molonc.2011.03.007untreated or treated with Cy, AdIL-12 or with a combination
of both. We found that Tregs from untreated mice (saline
group) produced high levels of IL-10 and TGF-b (mean  SEM
[mm3]: 172  8, and 3820  213 pg/ml, respectively; (Fig. 3C
and D). In contrast, we observed that Tregs of mice treated
with a single agent (Cy or AdIL-12) produced significantly
lower amounts of both cytokines (IL-10: 41  5 or 62  11 pg/
ml, respectively [p < 0,05 vs. saline]; TGF-b: 926  35 or
866  42 pg/ml, respectively [p < 0,01 vs. saline]). Importantly,
CyþAdIL-12 induced further inhibition of IL-10 andTGF-b pro-
duction by Tregs, in comparison to saline and single treat-
ments (11  8 pg/ml; p < 0,05 and 647  43 pg/ml; p < 0,01,
respectively). Consistently with these results, supernatants
of Tregs from untreated tumour-bearing mice inhibited DCs
stimulated allogeneic splenocytes proliferation (Fig. 3E). How-
ever, when supernatants of Tregs derived from CT26-bearing
animals treatedwith Cyþ AdIL-12 were assayed, a strong pro-
liferation activity was detected. Tregs cell viability from allastrointestinal carcinoma-induced immunosuppression and
hosphamide and gene transfer of IL-12, Molecular Oncology
Fig. 2 e Re-infusion of Tregs in CT26-bearing mice treated with the combination Cy D AdIL-12. (A) Tumour growth: BALB/c mice were s.c.
inoculated with 5 3 105 CT26 cells into the right flank (day 0) and tumours were allowed to reach 85 mm3 before the treatment began. Animals
(n [ 6/group) were treated with saline or Cy (50 mg/kg i.p., day 8) D AdIL-12 (109 TCID50 i.t., day 9). In addition,saline or Cy D AdIL-12-
treated mice were inoculated i.v. on days 11 and 13 with 1 3 106 CD4DCD25D T cells (Tregs) isolated from untreated tumour-bearing mice.
Tumour volume was assessed twice a week by calliper. The experiment was performed four times. Data are expressed as mean (bars, SEM).
KruskaleWallis test, day 28: Cy D AdIL-12 vs. saline and Cy D AdIL-12DTregs (*p< 0.05). B) Survival: KaplaneMeier, log rank test,
(**p< 0.01). C) In vivo distribution pattern of re-infused Tregs: Cy D AdIL-12-treated mice were inoculated with 1 3 106 fastDiO-dyed
CD4DCD25D T cells (i.v; days 11 and 13) and biodistribution was analysed by flow cytometry. The results shown represent three independent
experiments.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 1 ) 1e1 46groups was confirmed by trypan blue exclusion test (not
shown); no evidence of apoptosis was observed by TUNEL as-
say in all groups (data no shown). Altogether, these results
suggest that treatment of CT26-bearing mice with
Cy þ AdIL-12 reverts the inhibitory activity of Tregs on DCs,
probably by reduction of IL-10 and/or TGF-b secretion.
3.4. Depletion of MDSCs induced by the combination of
Cy with AdIL-12 is reverted after re-infusion of Tregs
It has been demonstrated that MDSCs contribute to generate
an immunosuppressive microenvironment leading to tumour
progression (Huang et al., 2006). We decided to investigate
whether Cy þ AdIL-12 could affect the number of splenic
MDSCs. The prevalence of CD11bþGr1þ cells (Bronte et al.,
1998) was determined in spleens derived from CT26
tumour-bearing mice treated with Cy, AdIL-12 or the combi-
nation by flow cytometry. We observed that Cy or AdIL-12
as a single treatment induced a slight decrease in the amount
of MDSCs in comparison to the saline group. However,
Cy þ AdIL-12 induced a 3-fold decrease in the percentage of
Please cite this article in press as: Malvicini, M. et al., Reversal of g
induction of antitumoural immunity by a combination of cyclop
(2011), doi:10.1016/j.molonc.2011.03.007splenic MDSCs ( p < 0.01; Fig. 4A). Interestingly, these reduced
levels of MDSCs induced after Cy þ AdIL-12 treatment
returned to baseline when Tregs from untreated tumour-
bearing mice were adoptively transferred (Fig. 4B). These
results suggest that the combined treatment affect the pro-
portion of MDSCs. Also, the restitution of MDCSs levels after
adoptive transfer of Tregs in Cy þ AdIL-12-treated mice
suggests a cross-regulation between both cell types in our
tumour model.
3.5. Adoptive transfer of in vitro expanded specific
IFN-g secreting CD4þ T lymphocytes derived from
Cy þ AdIL-12-treated mice has potent antitumoural effects
We have previously found that sequential treatment of mice
bearing CT26 with Cy followed by AdIL-12 significantly
increased IFN-g secretion by CD4þ T lymphocytes (Malvicini
et al., 2009). Here, we decided to further assess whether in vitro
expanded CD4þCD25 T cells (fromhere on CD4þ) might have
a direct therapeutic activity in vivo after i.v. injection in two
models. In a therapeutic model (Fig. 5A), CD4þ T cells from
astrointestinal carcinoma-induced immunosuppression and
hosphamide and gene transfer of IL-12, Molecular Oncology
Fig. 3 e Effect of combined therapy Cy D AdIL-12 on the interaction DC/Tregs. A) Quantification of IL-12: Data are expressed as mean (bars,
SEM). KruskaleWallis and Dunn’s multiple comparisons test: DC vs. DCDTregs (saline), *p< 0.05; DCDTregs (saline) vs. DCDTregs
(Cy D AdIL-12), ***p< 0.001. B) Phenotype of DCs (CD11cþMHC-IIþCD40þ). Mann Whitney test: DC vs. DCDTregs (saline), *p< 0.05;
DCDTregs (saline) vs. DCDTregs (CyD AdIL-12), *p< 0,05. The results shown represent three independent experiments. IL-10 (C)and TGF-
b (D) secretion by Tregs: Mann Whitney test, saline vs. Cy, AdIL-12, and Cy D AdIL-12, *p< 0.05; Cy D AdIL-12 vs. Cy and AdIL-12;
#p< 0.05. (E) Effect of Tregs supernatants (SN) on allogeneic spleen cell (SC) proliferation under stimulation with mitomycin C-treated DC.
(3H-Thymidine). Mann Whitney test, SCDDC vs. SCDDCDTregs SN (saline), ***p< 0.001; SCDDCDTregs SN (saline) vs. SCDDCDTregs
SN (Cy D AdIL-12), ***p< 0.001.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 1 ) 1e1 4 7mice treatedwith Cy or AdIL-12 as single agentswere devoid of
any significant effect on tumour growth and survival. On the
contrary, CD4þ T cells from mice treated with Cy þ AdIL-12
showed a significant reduction of tumour volume (89% vs. sa-
line group at day 23, p < 0,05; 81% and 78% vs. Cy and AdIL-12
groups, respectively; at day 28, p< 0,05) and an increase in ani-
mal survival ( p< 0.01). Similar resultwas obtainedwhenCD4þ
Tcells fromcombined treatmentwereadoptively transferred in
a preventive tumour model (Fig. 5B). On the other hand, we in-
vestigated the in vitro cytotoxic activity of CD4þ T cells used
for in vivo experiments and saw that cells derived frommice re-
ceiving thecombined treatmentdisplayedasignificantlyhigher
lytic activity against CT26 cells ( p< 0.001 vs. saline; p< 0.01 vs.
Cy or AdIL-12) and produced higher levels of IFN-g in compari-
son with control group ( p < 0.001 vs. saline; p < 0.01 vs. Cy orPlease cite this article in press as: Malvicini, M. et al., Reversal of g
induction of antitumoural immunity by a combination of cyclop
(2011), doi:10.1016/j.molonc.2011.03.007AdIL-12) (Fig. 5C). The specificity of cytotoxic effect was con-
firmed against BNL cells.
3.6. Cy þ AdIL-12 is highly effective in two stringent
gastrointestinal cancer models
In order to examine whether combined treatment exert anti-
tumoural effects in aggressive tumourmodelswe investigated
its therapeutic efficacy in a liver metastatic CRC model using
CT26 cells and also against an established pancreatic cancer
model using Panc02 cells. For this purpose, we injected CT26
cells into the liver of mice (day 0), treated with Cy (day 10)
and 24 h later with AdIL-12. Fig. 6A (left panel) shows that
no significant antimetastatic effect was observed when only
Cy and AdIL-12 were administered, whereas the combinedastrointestinal carcinoma-induced immunosuppression and
hosphamide and gene transfer of IL-12, Molecular Oncology
Fig. 4 e (A) Effect of combined treatment Cy D AdIL-12 on splenic MDSCs (CD11bþGr1þ): Mann Whitney test, saline vs. Cy D Ad-12
(**p< 0.01). Data are representative of three independent experiments (n[ 5/group per experiment) B) Effect of in vivo administration of Tregs on
splenic MDSCs in mice treated with the combination CyD AdIL-12. Mann Whitney test, CyD AdIL-12 vs. Saline, **p< 0,01 and CyD AdIL-12
plus Tregs, #p< 0.05. Data are representative of two independent experiments (n [ 6/group per experiment).
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 1 ) 1e1 48therapy showed a significant reduction in metastases growth
(98% vs. saline group, at day 20, p< 0.001). Therapeutic efficacy
of the combination was superior to each individual agent
(mean metastases volumeSE [mm3] at day 20: Cy þ AdIL-
12: 15,6  11,7; Cy: 191  87,4; and AdIL-12: 306  167;
p < 0.01) and complete metastases regressions were observed
in 7 out of 15 animals (47% vs. 0% in saline and single agents
groups). In addition, survival ofmice receiving combined ther-
apy was significantly higher than the controls ( p < 0.001;
Fig. 6A; right panel). Remarkably, Cy followed by AdIL-12
showed a potent antitumoural effect on Panc02 tumour nod-
ules. Animals treated only with Cy or AdIL-12 showed a signif-
icant reduction in tumour volumewith respect to saline groupPlease cite this article in press as: Malvicini, M. et al., Reversal of g
induction of antitumoural immunity by a combination of cyclop
(2011), doi:10.1016/j.molonc.2011.03.007(70% and 74% at day 54, respectively). However, no complete
tumour regression was observed in mice treated with a single
therapy. In contrast, the combined therapy resulted in
a marked reduction in tumour volume (95% vs. saline group,
at day 54; p < 0,05) and complete tumour regressions in 40%
of animals (4/10) (Fig. 6B, left panel). Importantly, the com-
bined treatment produced a significant reduction in tumour
growth in comparison to the effects of each single agent
(mean tumour volume  SE [mm3] at day 54; Cy þ AdIL-12:
209  127; Cy: 1330  358; AdIL-12: 1177  173; p < 0.05). Sur-
vival of mice receiving combined therapy was also signifi-
cantly increased in comparison to mice receiving individual
therapy or saline ( p < 0.001, Fig. 6B; right panel). Analysis ofastrointestinal carcinoma-induced immunosuppression and
hosphamide and gene transfer of IL-12, Molecular Oncology
Fig. 5 e Antitumour effect of in vitro expanded CD4D T-lymphocytes from CT26-bearing mice treated with Cy, AdIL-12 or CyD AdIL-12. (A)
Therapeutic model: BALB/c mice were s.c. inoculated with 53 105 CT26 cells into the right flank (day 0) and when tumours reached 65 mm3 in size
(day 6) the mice were treated with vitro expanded CD4D cells (2,5 3 106 i.v) from different experimental groups (n[ 4/group) (left panel). Data
are expressed as mean (bars, SEM). Mann Whitney test, days 23 and 28: CD4DCD25L (Cy D AdIL-12) vs. CD4DCD25L (saline, Cy and
AdIL-12), *p< 0.05. Survival (right panel). KaplaneMeier, log rank test, **p< 0.01. Data are representative of three independent experiments.
B) Preventive model: BALB/c mice (n [ 4/group) were simultaneously inoculated with 5 3 105 CT26 cells s.c. into the right flank and adoptive
transfer of 2,5 3 106 CD4D cells at the same time (day 0) (left panel). Data are expressed as mean (bars, SEM). Mann Whitney test, days 23 and
26:CD4DCD25L (CyD AdIL-12) vs. CD4DCD25L (saline, Cy and AdIL-12), *p< 0.05. Survival (right panel). KaplaneMeier, log rank test,
**p< 0.01. Data are representative of three independent experiments. C) Specific CTL activity (leftt panel): CD4D T cells from different
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M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 1 ) 1e1 410the in vivo interaction between both treatments was per-
formed by the fractional product method (FTV) (Yokoyama
et al., 2000). Fig. 6C summarises the relative tumour volume
of different groups at 4 different time points. On day 29 after
treatment, in the combination group there was a 1.3-fold im-
provement in the antitumour efficacy when compared to the
expected additive effect. On days 33 and 36, Cy þ AdIL-12
showed a 1.4-fold increase in the inhibition of tumour growth
over an additive effect (expected fractional tumour volume).
Moreover, on day 40 the increase was of 1.7-fold over the ad-
ditive effect. These results allow us to conclude that
Cy þ AdIL-12 has a synergistic effect on pancreatic carcinoma
growth inhibition. Similar doses of control adenovirus (Adb-
Gal), alone or in combination with Cy, did not produce any sig-
nificant change of tumour growth in both experimental
models (data no shown). In both tumour models, the com-
bined Cy plus AdIL-12 strategy was well tolerated with no
signs of toxicity (data not shown). Altogether, these results
show that the antitumour effects of the combined treatment
can be achieved in very aggressive tumour models including
pancreatic cancer.4. Discussion
A number of immunotherapy strategies for advanced GIC are
currently under preclinical and clinical evaluation (Mazzolini
et al., 2007). However, there is a frustrating inconsistency in
the correlation between biological and clinical responses.
The reasons for the mentioned data discrepancies are mani-
fold but the presence of strong mechanisms of immune es-
cape induced by tumours appears to be important (Clark
et al., 2009; Croci et al., 2007). Thus, it seemed reasonable to
explore immunotherapy strategies aimed at inducing rever-
sion of tolerogenic processes in tumour-bearing hosts, such
as those induced by Tregs (Zou, 2006).
We have previously demonstrated the synergistic antitu-
moural effect of sequential systemic administration of sub-
optimal Cy doses followed by immuno-gene therapy with
AdIL-12 in mice with CRC (Malvicini et al., 2009). One impor-
tant finding was that, regardless of the individual response
of eachmouse, the synergistic antitumour activity was associ-
ated with depletion of regulatory T cells.
We analysed the levels of Tregs after treatment with the
combination and classified them according to the treatment
response in R and NR mice. As a result, we observed that NR
mice failed to significantly decrease Tregs significantly in
spleen, peripheral blood, and inside tumours. The relevance
of Tregs depletion to achieve a therapeutic response in our
model was consistent when the efficacy of Cy þ AdIL-12 was
completely abolished following reconstitution of Tregs byexperimental groups (n[ 4/group) were isolated and stimulated in vitro wit
CTL activity was evaluated against CT26 and BNL cells. The percentage
Detection Kit and calculated according to the following formula: ([abs 492
abs492 nm background]) 3 100. Mann Whitney test, CyD AdIL-12 vs. sal
Data represent the mean of triplicate cultures. Quantification of IFNg (right
after its isolation and in vitro stimulation as described above. Data are exp
comparisons test: Cy D AdIL-12 vs. saline, ***p< 0.001; Cy D AdIL-12
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with adoptive therapy in Cy þ AdIL-12-treated mice (Fig. 2C)
were similar to the percentages of Tregs found in NR mice
(Fig. 1B; 1D). Considering that Tregs are up regulated in cancer
and that they induce a detrimental effect on the immune sys-
tem, strategies aimed at reducing Tregs number may increase
the efficacy of any immunotherapy (Curiel et al., 2004;
Ormandy et al., 2005; Sakaguchi et al., 2001). A myriad of in-
hibitory mechanisms have been proposed to explain the im-
munosuppression induced by Tregs, including secretion of
cytokine suppressors and the induction of apoptosis/cell cycle
arrest on effector T cells (Tang and Bluestone, 2008). It has also
been suggested that Tregs could modulate the maturation
and/or function of DCs (Larmonier et al., 2007; Onishi et al.,
2008). Indeed, intravital microscopy studies have suggested
that Tregs contact DCsmore frequently than potential effector
T cell targets (Bluestone and Tang, 2005). Taking into account
the current data regarding Tregs function in cancer and to the
way tumour cells drive Tregs induction, we decided to inves-
tigate the immunosuppressive effects of Tregs derived from
tumour-bearing mice and the effects of the combined Cy
and AdIL-12 treatment on their regulatory capacity (Beyer
and Schultze, 2006; Ghiringhelli et al., 2005).
Previously we demonstrated that in vivo treatment with
CyþAdIL-12 affected thematuration status of DCs. Currently,
we provide new evidence showing that this effect is mediated,
at least in part, by Tregs. Co-cultures of na€ıve DC with Tregs
from untreated animal tumours resulted in a significant inhi-
bition of IL-12 production as well as in MHC-II and CD40 ex-
pression by DCs. More importantly, the inhibitory activity of
Tregs on the maturation/activation status of DCs was com-
pletely abolished when Tregs derived frommice that received
Cy þ AdIL-12 were used.
The mechanisms used by Tregs to generate immunosup-
pression remain conflictive and controversial. Direct cellecell
interaction between Tregs and their target cells (effector
T cells or DCs) has been established as a prerequisite to exert
their immunoregulatory activity (Vignali et al., 2008). On the
other hand, the role of soluble factors, such as IL-10 and
TGF-b has also been investigated extensively (Dieckmann
et al., 2001; Takahashi et al., 1998; Thornton and Shevach,
1998). In the present work, we have detected high levels of
both cytokines in supernatants of Tregs isolated from spleen
of untreated tumours. These supernatants containing high
levels of IL-10 and TGF-b were able to inhibit allogeneic sple-
nocytes proliferation under stimulation with DCs. It is impor-
tant to note that Cy þ AdIL-12 significantly reduced the
production of IL-10 and TGF-b by Tregs and also abolished
their inhibitory effect on lymphocyte proliferation. Alto-
gether, our results suggest that treatment of CRC-bearing
mice with Cy þ AdIL-12 not only induces CD4þCD25þFoxp3þh mitomycin C-treated splenocytes and CT26 cells for 5 days. Specific
of specific cytotoxicity was quantified whit the LDH Cytotoxicity
nm experimental - abs 492 nm background])/[abs 492 nm maximum -
ine, ***p< 0.001; CyD AdIL-12 vs. Cy and AdIL-12, ###p< 0.01.
panel): The amount of IFN-g secreted by CD4DT cells was evaluated
ressed as mean (bars, SEM). KruskaleWallis and Dunn’s multiple
vs. Cy and AdIL-12, ##p< 0.01.
astrointestinal carcinoma-induced immunosuppression and
hosphamide and gene transfer of IL-12, Molecular Oncology
Fig. 6 e Effect of combined treatment CyD AdIL-12 on aggressive GIC models. A) Experimental liver metastases of CRC (CT26). Left panel, Liver
metastases volume: BALB/c mice received an intra-hepatic injection of 5 3 105 CT26 cells (day 0). Mice were distributed in different experimental
groups and treated with saline (n [ 6); Cy (50 mg/kg i.p; day 8, n [ 6); AdIL-12 (109 TCID50 i.t; day 9, n [ 6); or Cy D AdIL-12 (n [ 8).
Metastases volume was measured at day 20. Data are representative of three independent experiments. Mann Whitney test: Cy D AdIL-12 vs.
saline (***p< 0.001); Cy D AdIL-12 vs. AdIL-12 or Cy (##p< 0.01). Right panel, Survival: KaplaneMeier, log rank test, (***p< 0.001). B)
Pancreatic tumour model (Panc02). Left Panel, Tumour growth: C57BL/6 mice were inoculated s.c. in the right flank with 5 3 105 Panc02 cells.
Treatments began when tumours reached 85 mm3 in size. Animals were treated with saline (n[ 6), Cy (50 mg/kg i.p; day 8, n[ 5), AdIL-12 (109
TCID50 i.t; day 9, n [ 5), or Cy D AdIL-12 (n [ 6). Tumour growth was assessed twice a week by calliper. Data are expressed as mean (bars,
SEM). Data are representative of three independent experiments. Mann Whitney test: CyD AdIL-12 vs. Cy or AdIL-12 (*p< 0.05). Right panel,
Survival: KaplaneMeier, log rank test (***p< 0.001). C) Analysis of the in vivo interaction between Cy and AdIL-12 by the fractional product
method (FTV) in Panc02 model. a FTV (experimental mean tumour volume)/(control mean tumour volume); b Day after treatment onset; c (Cy
mean FTV) 3 (AdIL-12 mean FTV); d R [ Expected FTV/Observed FTV. A ratio>1 indicates a synergistic effect, and a ratio<1 indicates
a less than additive effect.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 1 ) 1e1 4 11T cell depletion but also modifies its functionality, at least by
reduction of IL-10 and TGF-b production. Our present results
strongly suggest that depletion of Tregs and/or inhibition of
Tregs ability to induce immunosuppression are keyPlease cite this article in press as: Malvicini, M. et al., Reversal of g
induction of antitumoural immunity by a combination of cyclop
(2011), doi:10.1016/j.molonc.2011.03.007immunoregulatorymechanisms associatedwith the synergis-
tic antitumour effects achieved with Cy þ AdIL-12.
Recently, myeloid-derived suppressor cells (MDSCs) have
been recognized as a cell population that can negativelyastrointestinal carcinoma-induced immunosuppression and
hosphamide and gene transfer of IL-12, Molecular Oncology
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 1 ) 1e1 412regulate T-cell functions (Gabrilovich et al., 2001). These cells
can act by inhibiting both the innate and adaptive immune re-
sponses (Huang et al., 2006). MDSCs are a heterogeneous pop-
ulation of myeloid cells that includes macrophages,
granulocytes and other cells that express Ly-6C/G (recognized
by Gr-1 antibody) and CD11b in mice and suppress immune
responses in vivo and in vitro (Gabrilovich and Nagaraj, 2009).
It has been observed that elimination of MDSC by antibodies
or cytotoxic agents such as gemcitabine in mouse tumour
models increased antitumour responses (Ko et al., 2010;
Suzuki et al., 2005) In our study, we analysed the phenotype
and frequency of CD11bþGr-1þ MDSCs in spleen of mice
with CT26 tumours treated with Cy, AdIL-12 or a combination
of both. While the administration of Cy or AdIL-12 as single
agents induced a slight decrease in the percentage of MDSCs
in comparison with the saline group, the combination of
Cy þ AdIL-12 produced a significant reduction of MDSCs in
the spleens of tumour-bearingmice. However, other immuno-
suppressive CD11b populations, such as F4/80þ and CD11cþ
cells, might be involved but were not analysed.
In agreement with our findings in CT26 tumour-bearing
mice, recent data published by Medina-Echeverz et al. (2010),
demonstrated that Cy in combination with IL-12 depleted
not only Tregs but also tumour-infiltrating monocytic-MDCs
(Mo-MDSCs) in another colorectal carcinoma model (MC38
cells). Using this approach, they observed that recruitment
of inflammatory monocytes/macrophages (IMC) into tumour
microenvironment after the elimination of Mo-MDSC by
Cy þ IL-12 has a key role for the observed antitumoural effect
(Medina-Echeverz et al., 2010)
In our tumour model the immune rejection of established
CT26 tumours was clearly affected by negative regulatory
mechanisms linked to an increase in number and function
of Tregs andMDSCs.We demonstrated that these negative in-
fluences could be overcome by the combination of Cy with
AdIL-12. More importantly, the combined therapy not only
has reverted immunosuppressive mechanisms induced dur-
ing tumour progression but also generated a strong cytotoxic
immune response against tumour cells mediated by specific
IFN-g secreting CD4þ T lymphocytes.
The majority of immune therapy strategies to treat cancer
have directed to the generation of CD8þ T cell responses
against tumour-associated antigens. CD4þT cells have the
ability to sustain CTL responses but can also function as effec-
tor cells either by production of potent cytokines (such as IFN-
g) or by exhibiting anticancer cytotoxic activity (Appay et al.,
2002; Haigh et al., 2008; Spaapen et al., 2010). In our work,
the in vitro expanded specific IFN-g secreting CD4þ T lympho-
cytes generated by Cy þ AdIL-12 have demonstrated to be ef-
fective in both a preventive and a therapeutic model using
CT26 tumourmodel.We assume that the induction of high cy-
tolytic activity and the potent Th1-type response in vivomight
be the cause for the profound antitumour effects observed and
could be also exploited in the future in combinationwith other
immunostimulatory strategies.
The use of low-dose Cy combined with sub-therapeutic
AdIL-12 induces significant regressions in two different and
aggressive tumour models: the CT26 liver metastatic model
and the pancreatic cancermodel. In this studywe have shown
by the fractional product method that the combinedPlease cite this article in press as: Malvicini, M. et al., Reversal of g
induction of antitumoural immunity by a combination of cyclop
(2011), doi:10.1016/j.molonc.2011.03.007treatment has also a synergistic effect for pancreatic carci-
noma. Thus, Cy þ AdIL-12 based treatment is a promising im-
munotherapy among the limited therapeutic options
suggesting the possibility of achieving high efficacy with IL-
12 without toxicity in more malignant tumour models. This
strategy could be improved in patients with disseminated dis-
ease by the use of tumour-targeted expression of IL-12 (Kerkar
et al., 2010). In conclusion, CyþAdIL-12 demonstrated efficacy
to block Tregs and MDSCs-mediated immunosuppressive tu-
mour environment and, simultaneously, to amplify the effec-
tor phase of the immune response by the induction of a potent
antitumour CTL activity. Considering our previous clinical ex-
perience of separate usage of IL-12 gene transfer and Cy in pa-
tients with cancer, it will be of interest to evaluate this
combination as a potential therapeutic strategy in advanced
GI carcinomas clinically.
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